Butensky & Cohen Financial Security’s Teva Pharmaceuticals TEVA Stock Holding History

Butensky & Cohen Financial Security’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-38,796	Closed	-$1.29M	–	109
2017 Q2	$1.29M	Buy	38,796 +3,445	+10%	+$107K	1.16%	48
2017 Q1	$1.13M	Buy	35,351 +1,834	+5%	+$62.6K	1.04%	55
2016 Q4	$1.22M	Buy	33,517 +5,095	+18%	+$203K	1.12%	50
2016 Q3	$1.31M	Buy	28,422 +2,580	+10%	+$135K	1.26%	46
2016 Q2	$1.3M	Buy	25,842 +1,515	+6%	+$80.7K	1.27%	48
2016 Q1	$1.3M	Sell	24,327 -40	-0.2%	-$2.35K	1.25%	47
2015 Q4	$1.6M	Sell	24,367 -400	-2%	-$24.7K	1.58%	26
2015 Q3	$1.4M	Sell	24,767 -2,520	-9%	-$163K	1.49%	27
2015 Q2	$1.61M	Sell	27,287 -1,570	-5%	-$96.8K	1.63%	25
2015 Q1	$1.8M	Sell	28,857 -610	-2%	-$35.5K	1.79%	17
2014 Q4	$1.7M	Buy	+29,467	New	+$1.64M	1.7%	23

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Butensky & Cohen Financial Security's TEVA Position: Q3 2017 in Review

Butensky & Cohen Financial Security sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 38,796 shares — an estimated $1.29M sold.

Butensky & Cohen Financial Security first reported a position in TEVA in Q4 2014 and held it in 11 quarters. The position peaked at $1.8M in Q1 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Butensky & Cohen Financial Security reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Butensky & Cohen Financial Security sold 38,796 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.29M.
Butensky & Cohen Financial Security first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 11 quarters.
Butensky & Cohen Financial Security's Teva Pharmaceuticals position peaked at $1.8M in Q1 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Butensky & Cohen Financial Security's 13F filing for Q3 2017, filed 20 Oct 2017.